▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3777 by analyst upside · 2026-09-28
BMY
Bristol-Myers Squibb Company
Healthcare · Market Cap $128B · P/E 13.8x
ANALYST PRICE TARGET
+6.1%
implied upside to consensus target
Current Price $62.86
Consensus Target $66.71
Bull Target $82.0
Bear Target $40.0
Analysts Covering 24
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
6
Hold
15
Sell
0
52-Week Low $42.52
52-Week High $68.64
YTD Return +20.1%
FUNDAMENTALS
Market Cap $128B
P/E Ratio (TTM) 13.8x
Forward P/E 9.6x
EPS (TTM) $4.54
PEG Ratio 17.50
Dividend Yield 4.01%
Revenue (TTM) $49.2B
Profit Margin 18.9%
52-WEEK RANGE
52-Week Low $42.52
52-Week High $68.64
Current Price $62.86
Bear Target $40.0
Bull Target $82.0
● Now $62.86 ● Target $66.71
TRADING DATA
Avg Volume 10.8M
YTD Return +20.1%
Analyst Count 24
Consensus Buy
Upside to Target +6.1%
Last Updated 2026-09-28

ANALYST SUMMARY

Bristol-Myers Squibb Company (BMY) is currently trading at $62.86 with a Wall Street consensus price target of $66.71, implying potential upside of 6.1% over the next 12 months. 24 analysts currently cover BMY, with a consensus rating of Buy - 38% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $82.0, while the most cautious has a target of $40.0.

BMY operates in the Healthcare sector with a market capitalisation of $128B. The stock is up 20.1% year-to-date and is currently trading near the upper end of its 52-week range of $42.52 – $68.64.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PFE +0.7%
Pfizer Inc.
$163B · P/E 37.7x · Hold
INCY +3.1%
Incyte Corporation
$25B · P/E 15.8x · Hold
BLFS -18.7%
BioLife Solutions, Inc.
$2B · P/E 38.5x · Hold
OMCL +71.9%
Omnicell, Inc.
$2B · P/E 40.1x · Buy
SNY +30.7%
Sanofi
$99B · P/E 22.3x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for BMY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler reit
Overweight → Overweight 2026-09-16 14% win rate (7 calls)
HSBC - Reiterated
Hold → Hold 2026-09-10 Building track record
Argus Research ↑ Upgrade
Hold → Buy 2026-08-05 Building track record
Citigroup - Reiterated
Neutral → Neutral 2026-08-03 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-07-31 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-07-31 43% win rate (7 calls)
Cantor Fitzgerald - Reiterated
Neutral → Neutral 2026-07-31 40% win rate (10 calls)
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-07-31 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
25/30
Consensus clarity
17/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →